ClinicalTrials.gov
ClinicalTrials.gov Menu

Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01007357
Recruitment Status : Terminated (Principal Investigator left institution; did not complete the study)
First Posted : November 4, 2009
Last Update Posted : November 13, 2015
Sponsor:
Collaborator:
Philips Medical Systems
Information provided by (Responsible Party):
University of Nebraska

Brief Summary:
This project will facilitate the optimization of body MR imaging at 3 Tesla.

Condition or disease Intervention/treatment Phase
Diffuse and Focal Abnormalities of the Liver and Pancreas Device: Body MR imaging Not Applicable

Detailed Description:
This project is meant to improve the image quality of multiple sequences at 3.0T applied to the abdominal and pelvic regions.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation
Study Start Date : December 2009
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
No Intervention: Body MRI healthy volunteers
Body MRI to optimize sequences in healthy individuals and in disorder subjects
Device: Body MR imaging
Body MR imaging will be performed to optimize sequences
Other Name: Body MR imaging performed to optimize sequences



Primary Outcome Measures :
  1. to optimize body MR imaging sequences [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects between ages of 19 and 65
  • Healthy volunteer subjects should not have any history of disease or symptoms - based on clinical history
  • Subjects with an underlying disorder (diffuse and focal abnormalities of the liver and pancreas)

Exclusion Criteria:

  • Inability to provide informed consent
  • A medical or contraindications that will prevent subjects from having a MRI
  • Subjects with severe renal dysfunction or patients on dialysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01007357


Locations
United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198-1045
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Sponsors and Collaborators
University of Nebraska
Philips Medical Systems
Investigators
Principal Investigator: Shahid Hussain, MD University of Nebraska

Responsible Party: University of Nebraska
ClinicalTrials.gov Identifier: NCT01007357     History of Changes
Other Study ID Numbers: 290-09
First Posted: November 4, 2009    Key Record Dates
Last Update Posted: November 13, 2015
Last Verified: November 2015